Neurobiological correlates of panic disorder and agoraphobia

Journal of Postgraduate Medicine

Volumn 47, Issue 1, 2001, Pages 55-61

  Al Haddad, M K ^a   Sequeira, R P ^a   Nayar, U ^a  

^a ARABIAN GULF UNIVERSITY   (Bahrain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CLONAZEPAM; DIAZEPAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LORAZEPAM; MONOAMINE OXIDASE INHIBITOR; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGORAPHOBIA; ARTICLE; BRAIN FUNCTION; CASE REPORT; CLINICAL FEATURE; COGNITIVE THERAPY; DYSPNEA; GENERAL PRACTICE; HEART PALPITATION; HUMAN; HYPERVENTILATION SYNDROME; MALE; NEUROBIOLOGY; PANIC; PSYCHOPHARMACOTHERAPY; SEDATION; SIDE EFFECT;

ADULT; AGORAPHOBIA; ANXIETY; HUMANS; MALE; MODELS, NEUROLOGICAL; PANIC DISORDER;

EID: 0035184942     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. On the longitudinal course of panic disorder: Development history and predictors of phobic complications
2. The changing nature of agoraphobic fears
3. Age of onset in different phobias
4. The genetics of panic disorder and agoraphobia
5. A family study of panic disorder
6. Agoraphobia, panic disorder and generalised anxiety disorder: Some implications of recent advances
7. Classification of neurotic disorders
8. Role of cognitive appraisal in panic related avoidance
9. Hyperventilation syndrome: Infrequently recognised common expressions of anxiety and stress
10. Breathing retraining: A rational placebo?
11. Response to hyperventilation in a group of patients with panic disorder
12. Hyperventilation in panic attacks: Ambulant monitoring of transcutaneous carbon dioxide
13. A neuroanatomical hypothesis for panic disorder
14. Genetic factors in anxiety disorders
15. Functional localization in temporal and deep Sylvian areas
16. The treatment of panic disorder
17. Neuroanatomic correlate of CCK-4 induced panic attacks in healthy humans: A comparison of two time points
18. Noradrenergic function in panic anxiety: Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder
19. Cerebral glucose metabolism in women with panic disorder
20. Antianxiety action of benzodiazepines decrease in activity of serotonin neurons in the punishment system
21. Immunocytochemical Evidence for serotoninergic innervatory of noradrenergic neurons in nucleus locus coeruleus
22. Towards an integrated neurobiology of panic disorder
23. Anxiety and the effects of sodium lactate assessed clinically and physiologically
24. Carbon dioxide sensitivity in panic anxiety: Ventilatory and anxiogenic response to carbon dioxide in healthy subjects and patients with panic anxiety before and after alprazolam treatment
25. Decreased brain GABA benzodiazepine receptor binding in panic disorder
26. 2C receptor agonists and fluoxetine in a model of panic like anxiety in rats
27. A cognitive approach to panic
28. Cognition and agoraphobia bias in the interpretation of threat
29. Implicit and explicit memory bias in anxiety
30. Discrimination of threat cues without awareness in anxiety states
31. Cognitive therapy for panic disorder
32. Applied relaxation: Description of a coping technique and review of controlled studies
33. The treatment of panic disorder in a clinical setting: A 12-month naturalistic study
34. Clonazepam Panic Disorder Dose-Response Study Group. Clonazepam in the treatment of panic disorder with or without agoraphobia: A dose-response study of efficacy, safety, and discontinuance
35. Clomipramine treatment of panic disorder: Pros and cons
36. Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia
37. Combined pharmacotherapy and cognitive behaviour therapy in the treatment of panic disorder
38. Benzodiazepines and exposure-based cognitive behaviour therapies for panic disorder: Conclusions from combined trials
39. Does Chronic drug intake affect the long term outcome of group cognitive behaviour therapy in panic disorder with or without agoraphobia?
40. Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care
41. Agoraphobia and panic disorder: 3.5 years after alprazolam and or exposure treatment
42. Sertraline in the treatment of panic disorder: A double blind multicentre trial
43. Sertraline in the treatment of panic disorder: A flexible dose multicentric trial
44. Antidepressants in panic disorder
45. Service utilization and expenditures for the treatment of panic disorder